keyword
MENU ▼
Read by QxMD icon Read
search

sorafenib in papillary thyroid cancer

keyword
https://www.readbyqxmd.com/read/27742787/thyroid-cancer-risk-stratified-management-and-individualized-therapy
#1
Friedhelm Raue, Karin Frank-Raue
Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer (DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), is the most frequent subtype of thyroid cancer; more rare subtypes are medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC). The incidence of DTC has increased rapidly in recent years due to the more frequent use of imaging methods such as ultrasound of the neck and fine-needle aspiration (FNA) of thyroid nodules...
October 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27703298/management-of-the-patient-with-aggressive-and-resistant-papillary-thyroid-carcinoma
#2
Rame Miftari, Valdete Topçiu, Adem Nura, Valdete Haxhibeqiri
PURPOSE: Papillary carcinoma is the most frequent type of thyroid cancer and was considered the most benign of all thyroid carcinomas, with a low risk of distant metastases. However, there are some variants of papillary thyroid carcinoma that have affinity to spread in many organs, such as: lymph nodes, lungs and bones. AIM: The aim of this study was presentation of a case with papillary carcinoma of the thyroid gland, very persistent and resistant in treatment with I 131...
July 27, 2016: Medical Archives
https://www.readbyqxmd.com/read/27618325/current-concepts-in-the-molecular-genetics-and-management-of-thyroid-cancer-an-update-for-radiologists
#3
Tatiana Kelil, Abhishek R Keraliya, Stephanie A Howard, Katherine M Krajewski, Marta Braschi-Amirfarzan, Jason L Hornick, Nikhil H Ramaiya, Sree Harsha Tirumani
Substantial improvement in the understanding of the oncogenic pathways in thyroid cancer has led to identification of specific molecular alterations, including mutations of BRAF and RET in papillary thyroid cancer, mutation of RAS and rearrangement of PPARG in follicular thyroid cancer, mutation of RET in medullary thyroid cancer, and mutations of TP53 and in the phosphatidylinositol 3'-kinase (PI3K)/AKT1 pathway in anaplastic thyroid cancer. Ultrasonography (US) and US-guided biopsy remain cornerstones in the initial workup of thyroid cancer...
September 2016: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/27207700/treatment-of-advanced-thyroid-cancer-with-targeted-therapies-ten-years-of-experience
#4
REVIEW
David Viola, Laura Valerio, Eleonora Molinaro, Laura Agate, Valeria Bottici, Agnese Biagini, Loredana Lorusso, Virginia Cappagli, Letizia Pieruzzi, Carlotta Giani, Elena Sabini, Paolo Passannati, Luciana Puleo, Antonio Matrone, Benedetta Pontillo-Contillo, Valentina Battaglia, Salvatore Mazzeo, Paolo Vitti, Rossella Elisei
Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such as papillary and follicular cancers, which have survival rates of approximately 95% at 40 years. However, 15-20% of cases became radioiodine refractory (RAI-R), and until now, no other treatments have been effective. The same problems are found in cases of poorly differentiated (PDTC) and anaplastic (ATC) thyroid cancers and in at least 30% of medullary thyroid cancer (MTC) cases, which are very aggressive and not sensitive to radioiodine...
April 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/26786320/-secondary-solid-tumors-in-thyroid-cancer-patients-treated-with-the-multi-kinase-inhibitor-sorafenib-may-present-diagnostic-challenges
#5
Tatiana C Schneider, Ellen Kapiteijn, Tom van Wezel, Jan W A Smit, Jacobus J M van der Hoeven, Hans Morreau
BACKGROUND: Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side effect of sorafenib is the occurrence of cutaneous squamous tumors. CASE PRESENTATION: Here we describe three patients with a history of sorafenib treatment for advanced radioactive iodine refractory papillary thyroid cancer (two with a BRAF c...
January 19, 2016: BMC Cancer
https://www.readbyqxmd.com/read/26635725/molecular-targeted-therapies-of-aggressive-thyroid-cancer
#6
REVIEW
Silvia Martina Ferrari, Poupak Fallahi, Ugo Politti, Gabriele Materazzi, Enke Baldini, Salvatore Ulisse, Paolo Miccoli, Alessandro Antonelli
Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account >90% of thyroid cancer (TC) [papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%], while medullary thyroid cancer (MTC) accounts <5%. Complete total thyroidectomy is the treatment of choice for PTC, FTC, and MTC. Radioiodine is routinely recommended in high-risk patients and considered in intermediate risk DTC patients. DTC cancer cells, during tumor progression, may lose the iodide uptake ability, becoming resistant to radioiodine, with a significant worsening of the prognosis...
2015: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/26314551/the-distribution-of-braf-gene-fusions-in-solid-tumors-and-response-to-targeted-therapy
#7
Jeffrey S Ross, Kai Wang, Juliann Chmielecki, Laurie Gay, Adrienne Johnson, Jacob Chudnovsky, Roman Yelensky, Doron Lipson, Siraj M Ali, Julia A Elvin, Jo-Anne Vergilio, Steven Roels, Vincent A Miller, Brooke N Nakamura, Adam Gray, Michael K Wong, Philip J Stephens
Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the FoundationOne™ or FoundationOne Heme™ comprehensive genomic profiling assays. BRAF fusions involving the intact in-frame BRAF kinase domain were observed in 55 (0.3%) of 20,573 tumors, across 12 distinct tumor types, including 20 novel BRAF fusions...
February 15, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/26207356/phase-2-trial-of-sorafenib-in-children-and-young-adults-with-refractory-solid-tumors-a-report-from-the-children-s-oncology-group
#8
MULTICENTER STUDY
AeRang Kim, Brigitte C Widemann, Mark Krailo, Nalini Jayaprakash, Elizabeth Fox, Brenda Weigel, Susan M Blaney
BACKGROUND: Sorafenib is an oral small molecule inhibitor of multiple kinases controlling tumor growth and angiogenesis. The purpose of the phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics of sorafenib in children and young adults with relapsed or refractory tumors including rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma (HCC), and papillary thyroid carcinoma (PTC). PROCEDURE: Sorafenib, 200 mg/m(2) /dose, was administered every 12 hr continuously for 28 day cycles using a two-stage design in two primary strata (rhabdomyosarcoma and Wilms tumor) and two secondary strata (HCC and PTC)...
September 2015: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/26134286/2-deoxy-d-glucose-can-complement-doxorubicin-and-sorafenib-to-suppress-the-growth-of-papillary-thyroid-carcinoma-cells
#9
Shuo-Yu Wang, Yau-Huei Wei, Dar-Bin Shieh, Li-Ling Lin, Shih-Ping Cheng, Pei-Wen Wang, Jiin-Haur Chuang
Tumor cells display a shift in energy metabolism from oxidative phosphorylation to aerobic glycolysis. A subset of papillary thyroid carcinoma (PTC) is refractory to surgery and radioactive iodine ablation. Doxorubicin and sorafenib are the drugs of choice for treating advanced thyroid cancer but both induce adverse effects. In this study, we assessed the anti-cancer activity of 2-deoxy-d-glucose (2-DG) alone and in combination with doxorubicin or sorafenib in PTC cell lines with (BCPAP) and without (CG3) the BRAFV600E mutation...
2015: PloS One
https://www.readbyqxmd.com/read/26112458/aggressive-thyroid-cancer-targeted-therapy-with-sorafenib
#10
A Corrado, S M Ferrari, U Politti, V Mazzi, M Miccoli, G Materazzi, A Antonelli, S Ulisse, P Fallahi, P Miccoli
Sorafenib (Nexavar), is a multikinase inhibitor, which has demonstrated both anti proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumoral cells [c-RAF (proto-oncogene serine/threonine-protein kinase), BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3] and in tumor vessels [c-RAF, vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, and platelet-derived growth factor receptor β]. Sorafenib was initially approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma...
June 26, 2015: Minerva Endocrinologica
https://www.readbyqxmd.com/read/25879531/sorafenib-inhibits-intracellular-signaling-pathways-and-induces-cell-cycle-arrest-and-cell-death-in-thyroid-carcinoma-cells-irrespective-of-histological-origin-or-braf-mutational-status
#11
Martina Broecker-Preuss, Stefan Müller, Martin Britten, Karl Worm, Kurt Werner Schmid, Klaus Mann, Dagmar Fuhrer
BACKGROUND: Patients with dedifferentiated or anaplastic thyroid carcinomas currently lack appropriate treatment options. Kinase inhibitors are among the most promising new agents as alternative strategies. The BRAF- and multi-kinase inhibitor, sorafenib, has already shown antitumor effects in thyroid carcinoma patients in a phase III clinical trial. In this study we aim to better characterize molecular effects and efficacy of sorafenib against thyroid carcinoma cells with various histological origins and different BRAF mutational status...
March 26, 2015: BMC Cancer
https://www.readbyqxmd.com/read/25789503/new-therapies-for-dedifferentiated-papillary-thyroid-cancer
#12
REVIEW
Poupak Fallahi, Valeria Mazzi, Roberto Vita, Silvia Martina Ferrari, Gabriele Materazzi, David Galleri, Salvatore Benvenga, Paolo Miccoli, Alessandro Antonelli
The number of thyroid cancers is increasing. Standard treatment usually includes primary surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid remnant with radioactive iodine (RAI). Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will develop metastatic disease, which fails to respond to RAI, exhibiting a more aggressive behavior. The lack of specific, effective and well-tolerated drugs, the scarcity of data about the association of multi-targeting drugs, and the limited role of radioiodine for dedifferentiated thyroid cancer, call for further efforts in the field of new drugs development...
March 17, 2015: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/25768669/iodide-and-glucose-handling-gene-expression-regulated-by-sorafenib-or-cabozantinib-in-papillary-thyroid-cancer
#13
Maomei Ruan, Min Liu, Qianggang Dong, Libo Chen
CONTEXT: The aberrant silencing of iodide-handling genes accompanied by up-regulation of glucose metabolism presents a major challenge for radioiodine treatment of papillary thyroid cancer (PTC). OBJECTIVE: This study aimed to evaluate the effect of tyrosine kinase inhibitors on iodide-handling and glucose-handling gene expression in BHP 2-7 cells harboring RET/PTC1 rearrangement. MAIN OUTCOME MEASURES: In this in vitro study, the effects of sorafenib or cabozantinib on cell growth, cycles, and apoptosis were investigated by cell proliferation assay, cell cycle analysis, and Annexin V-FITC apoptosis assay, respectively...
May 2015: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/25548522/efficacy-of-sorafenib-in-advanced-differentiated-and-medullary-thyroid-cancer-experience-in-a-turkish-population
#14
Mustafa Benekli, Suayib Yalcin, Metin Ozkan, Emin Tamer Elkiran, Alper Sevinc, Devrim Cabuk, Hasan Senol Coskun, Berna Oksuzoglu, Banu Bayar, Akif Akbulat, Ahmet Ozet
BACKGROUND: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication. PATIENTS AND METHODS: Patients with advanced DTC and MTC were retrospectively identified from the Turkish Ministry of Health database. Data on these patients were prospectively collected before permission is granted to use sorafenib...
2015: OncoTargets and Therapy
https://www.readbyqxmd.com/read/25465739/targeted-therapy-a-new-hope-for-thyroid-carcinomas
#15
REVIEW
Francesco Perri, Luciano Pezzullo, Maria Grazia Chiofalo, Secondo Lastoria, Francesca Di Gennaro, Giuseppina Della Vittoria Scarpati, Francesco Caponigro
Thyroid carcinomas are rare and heterogeneous diseases representing less than 1% of all malignancies. The majority of thyroid carcinomas are differentiated entities (papillary and folliculary carcinomas) and are characterized by good prognosis and good response to surgery and radioiodine therapy. Nevertheless, about 10% of differentiated carcinomas recur and become resistant to all therapies. Anaplastic and medullary cancers are rare subtypes of thyroid cancer not suitable for radioiodine therapy. A small percentage of differentiated and all the anaplastic and medullary thyroid carcinomas often recur after primary treatments and are no longer suitable for other therapies...
April 2015: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/25309799/accelerated-disease-progression-after-discontinuation-of-sorafenib-in-a-patient-with-metastatic-papillary-thyroid-cancer
#16
Kyung-Jin Yun, Woohyeon Kim, Eun Hee Kim, Min-Hee Kim, Dong-Jun Lim, Moo-Il Kang, Bong-Yun Cha
Distant metastases from papillary thyroid carcinoma (PTC) are rare and are associated with a poor prognosis. Here, we describe a patient with metastatic PTC who was treated with a tyrosine kinase inhibitor (TKI, sorafenib) for several months that was acutely exacerbated by discontinuation. A 43-year-old male was diagnosed with PTC in February 2004 and underwent total thyroidectomy followed by two courses of high-dose radioactive iodine (RAI) therapy. Despite two additional courses of high-dose RAI therapy, lung and muscle metastases were developed...
September 2014: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/25309777/molecular-pathogenesis-and-targeted-therapies-in-well-differentiated-thyroid-carcinoma
#17
REVIEW
Jung Guk Kim
Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-γ, may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies...
September 2014: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/25298765/heart-failure-as-first-sign-of-development-of-cardiac-metastases-in-a-patient-with-diagnosis-of-papillary-thyroid-carcinoma-on-treatment-with-tyrosine-kinase-inhibitors-differential-diagnoses-and-clinical-management
#18
Gema Bruixola, Angel Segura, Javier Caballero, Ana Andrés, Encarnación Reche, Corina Escoín, Roberto Díaz-Beveridge
BACKGROUND: Cardiac metastases from papillary thyroid carcinoma are very uncommon. Their incidence is rising due to improvements in survival and diagnosis; nevertheless, our patient is the fourth case reported up to date. There are no clinical trials available in this scenario. Therefore, treatment choice is made based on clinical experience and case reports; notably, the largest case report series was prior to the approval for using tyrosine-kinase inhibitors in thyroid cancer. PATIENT: A 73-year-old lady had dedifferentiated papillary thyroid cancer with ongoing sorafenib...
May 2014: Case Reports in Oncology
https://www.readbyqxmd.com/read/25277206/fak-inhibition-with-small-molecule-inhibitor-y15-decreases-viability-clonogenicity-and-cell-attachment-in-thyroid-cancer-cell-lines-and-synergizes-with-targeted-therapeutics
#19
Shalana O'Brien, Vita M Golubovskaya, Jeffrey Conroy, Song Liu, Dan Wang, Biao Liu, William G Cance
Focal adhesion kinase (FAK) is up-regulated in thyroid cancer and small molecule FAK scaffolding inhibitor, Y15, was shown to decrease cancer growth in vitro and in vivo. We sought to test the effectiveness of Y15 in thyroid cancer cell lines, profile gene expression with Y15 compared with clinical trial FAK inhibitor PF-04554878, and use Y15 in novel drug combinations. Cell viability was decreased in a dose dependent manner in four thyroid cancer cell lines with Y15 and with higher doses in PF-04554878. Y397 FAK and total FAK were decreased with Y15 and decreased less with PF-04554878...
September 15, 2014: Oncotarget
https://www.readbyqxmd.com/read/25269412/pharmacological-suppression-of-the-ras-mapk-pathway-in-thyroid-carcinoma-cells-can-provoke-opposite-effects-on-cell-migration-and-proliferation-the-appearance-of-yin-yang-effects-and-the-need-of-combinatorial-treatments
#20
Alexander Glassmann, Jochen Winter, Dominik Kraus, Nadine Veit, Rainer Probstmeier
A major challenge in tumor therapy is the decrease or even the halting of cell proliferation and migration of cancerous cells. In the present study, we have analyzed the impact of a pharmacological blockade of the PI3K/Akt and MAPK/ERK1/2 signaling pathways on cell migration, proliferation and cell death in three human thyroid tumor cell lines that represent the main types of malignant thyroid carcinomas (B-CPAP, follicular; Cal-62, anaplastic; FTC-133, papillary thyroid carcinoma cells) and in which these pathways are constitutively activated...
December 2014: International Journal of Oncology
keyword
keyword
58925
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"